Kalbe Farma reported earnings results for the fiscal year 2016. For the year, the company posted a 8.3% year-on-year rise in fiscal year 2016 net sales. Net sales for the 12 months to 31 December 2016 reached IDR 19.367 trillion (USD 1.5 billion) from IDR 17.887 trillion a year earlier, driven mostly by stronger sales volume, better purchasing power, and controlled inflation rate. Operating profit climbed by 15.6% year-on-year to IDR 3.1 trillion in fiscal year 2016, equivalent to a 15.8% ratio of net sales, and net income increased by 13.5% year-on-year to IDR 2.3 trillion.

Kalbe Farma (Indonesia) is targeting sales growth of 8-9% in 2017, driven by 10-15 new products across different business divisions, including pharmaceuticals, consumer health, and nutrition. The company is also forecasting an operating profit margin of 14.5-15.5%, and has set aside a capital expenditure budget of IDR 1.2 trillion to expand manufacturing capacity.